US 12,409,198 B2
Vaccinia virus that induces cell fusion and use thereof
Takafumi Nakamura, Yonago (JP); Nozomi Kuwano, Yonago (JP); Motomu Nakatake, Yonago (JP); and Hajime Kurosaki, Yonago (JP)
Assigned to National University Corporation Tottori University, Tottori (JP); and Evolve Biotherapeutics Co., Ltd., Yonago (JP)
Appl. No. 17/610,777
Filed by National University Corporation Tottori University, Tottori (JP)
PCT Filed May 12, 2020, PCT No. PCT/JP2020/018976
§ 371(c)(1), (2) Date Nov. 12, 2021,
PCT Pub. No. WO2020/230785, PCT Pub. Date Nov. 19, 2020.
Claims priority of application No. 2019-091609 (JP), filed on May 14, 2019.
Prior Publication US 2022/0313761 A1, Oct. 6, 2022
Int. Cl. A61K 35/768 (2015.01); A61K 35/76 (2015.01); A61K 39/12 (2006.01); A61K 39/285 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01)
CPC A61K 35/768 (2013.01) [A61K 39/3955 (2013.01); A61P 35/00 (2018.01)] 13 Claims
 
1. An oncolytic vaccinia virus, which is deprived of functions of the K2L gene or the HA gene, or functions of the K2L gene and the HA gene, and further comprises deleting functions of the vaccinia virus growth factor (VGF) gene and O1L gene, and which has oncolytic effects of not growing in normal cells, growing specifically in cancer cells, specifically damaging cancer cells, induces cell fusion between infected cells, enhances a systemic anticancer immune activity, and induces cell death.